Healthcare - Biotechnology - NASDAQ - US
$ 1.97
-2.48 %
$ 156 M
Market Cap
-1.37
P/E
CASH FLOW STATEMENT
-102 M
OPERATING CASH FLOW
48.7 M
INVESTING CASH FLOW
4.05 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Tenaya Therapeutics, Inc.
| Net Income | -124 M |
| Depreciation & Amortization | 8.69 M |
| Capital Expenditures | -1.24 M |
| Stock-Based Compensation | 15.3 M |
| Change in Working Capital | -5.65 M |
| Others | 1.3 M |
| Free Cash Flow | -103 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (124.1) | (123.7) | (72.7) | (38.4) | (26.2) |
| Depreciation & Amortization | 8.7 | 6.5 | 3.0 | 2.5 | 2.0 |
| Deferred Income Tax | 0 | 0 | 0.2 | 33 K | 82 K |
| Stock Based Compensation | 15.3 | 11.5 | 3.0 | 0.7 | 0.4 |
| Other Operating Activities | 3.7 | 2.2 | 1.1 | 75 K | 64 K |
| Change in Working Capital | (5.6) | (0.8) | 4.7 | (0.2) | (0.2) |
| Cash From Operations | (102.1) | (104.4) | (60.8) | (35.4) | (24.1) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (1.2) | (20.6) | (25.1) | (9.8) | (2.9) |
| Other Items | 50.0 | 104.3 | (213.4) | 2.8 | (2.7) |
| Cash From Investing Activities | 48.7 | 83.7 | (238.6) | (7.0) | (5.6) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 13 K | 1 K | 3 K |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.2 | 0.4 | 20.4 | 147.3 | 30.5 |
| Cash From Financing Activities | 4.0 | 77.8 | 209.0 | 147.3 | 30.5 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (49.3) | 57.0 | (90.4) | 104.8 | 0.8 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (103.3) | (125.1) | (85.9) | (45.2) | (27.0) |